Difference between revisions of "Part:BBa K3989010"
(23 intermediate revisions by the same user not shown) | |||
Line 3: | Line 3: | ||
<partinfo>BBa_K3989010 short</partinfo> | <partinfo>BBa_K3989010 short</partinfo> | ||
− | In this construct, outer membrane-associated protein ClyA is used to display the plant immune elicitor [[Part:BBa_K3286138 | + | In this construct, outer membrane-associated protein ClyA ([[Part:BBa_K811000]]) is used to display the plant immune elicitor flg22 ([[Part:BBa_K3286138]]) to the surface of bacterial outermembrane vesicles (OMVs) to trigger plant immune responses. To make flg22 better recognized by plant immune receptor FLS2, we put mutiple linkers and a 3×FLAG tag between ClyA and flg22 to minimize the steric hindrance. |
+ | |||
+ | ===Usage and Biology=== | ||
+ | <html> | ||
+ | This construct can be used to enhance the plant immune responses triggered by OMVs, please see: <a href="https://2021.igem.org/Team:UZurich">2021 UZurich</a> | ||
+ | </html> | ||
+ | |||
+ | ====Characterization by team 2021 UZurich==== | ||
+ | |||
+ | By doing western blot using anti-FLAG antibody, we proved that ClyA-elicitor fusion proteins indeed exist in OMVs (Figure 1). | ||
[[File:ClyA_in_omp8_OMV.jpeg|500px]] | [[File:ClyA_in_omp8_OMV.jpeg|500px]] | ||
+ | |||
+ | Figure 1. ClyA protein with or without elicitor fused exists in outer membrane vesicles of <i>E. coli</i> omp8 strain. | ||
+ | |||
+ | The immunogenicities of engineered OMVs were first tested by Seedling Growth Inhibition (SGI) assay (Figure 2 & 3). In SGI assay, <i>A. thaliana</i> Col-0 seedlings were treated by immune elicitors (OMVs in our case) for 7-10 days, and lower seedling weight indicates that higher immune response is triggered (due to the trade-off between immunity and growth). Two <i>E. coli</i> strains were used, omp8 (Figure 2) and <i>tolB</i> (Figure 3), which can produce high and low immunogenic OMVs, respectively. For both strains, ClyA-flg22 and ClyA-elf18 OMVs seem to trigger stronger immune responses than OMVs containing only ClyA. However, the enhancement effect is more significant for <i>tolB</i> OMVs than omp8 OMVs. The reason might be that natural omp8 OMVs can already trigger strong immune responses, obscuring the additional immune responses triggered by flg22 or elf18. | ||
[[File:omp8 OMVs on col-0.jpeg|500px]] | [[File:omp8 OMVs on col-0.jpeg|500px]] | ||
+ | |||
+ | Figure 2. Evaluation of engineered <I>E. coli</i> omp8 OMVs' immunogenicities by SGI assay. | ||
[[File:tolB OMVs on col-0.jpeg|500px]] | [[File:tolB OMVs on col-0.jpeg|500px]] | ||
− | < | + | Figure 3. Evaluation of engineered <I>E. coli tolB</i> OMVs' immunogenicities by SGI assay. |
− | + | ||
+ | ROS (reactive oxygen species) burst assay was also used to test the immunogenicities of engineered OMVs (Figure 4), which shows how the leaf discs of <i>A. thaliana</i> Col-0 respond to OMV treatments within one to two hours. Both omp8 (Figure 4A, B) and <i>tolB</i> (Figure 4C, D) strains were used to produce OMVs, and both time-course ROS production curve (Figure 4A, C) and total ROS production (Figure 4B, D) are shown. Our results show that only ClyA-elf18 ([[Part:BBa_K3989011]]) OMVs, but not Cly-flg22 OMVs, can trigger significantly higher ROS production than ClyA-only OMVs, which is different from SGI assay where both constructs show enhancement effects. | ||
+ | |||
+ | [[File:ROS overall Col-0.png|700px]] | ||
+ | |||
+ | Figure 4. Evaluation of engineered OMVs' immunogenicities by ROS burst assay. | ||
<!-- --> | <!-- --> |
Latest revision as of 16:51, 20 October 2021
plant immune elicitor flg22 fused with ClyA for OMV display
In this construct, outer membrane-associated protein ClyA (Part:BBa_K811000) is used to display the plant immune elicitor flg22 (Part:BBa_K3286138) to the surface of bacterial outermembrane vesicles (OMVs) to trigger plant immune responses. To make flg22 better recognized by plant immune receptor FLS2, we put mutiple linkers and a 3×FLAG tag between ClyA and flg22 to minimize the steric hindrance.
Usage and Biology
This construct can be used to enhance the plant immune responses triggered by OMVs, please see: 2021 UZurich
Characterization by team 2021 UZurich
By doing western blot using anti-FLAG antibody, we proved that ClyA-elicitor fusion proteins indeed exist in OMVs (Figure 1).
Figure 1. ClyA protein with or without elicitor fused exists in outer membrane vesicles of E. coli omp8 strain.
The immunogenicities of engineered OMVs were first tested by Seedling Growth Inhibition (SGI) assay (Figure 2 & 3). In SGI assay, A. thaliana Col-0 seedlings were treated by immune elicitors (OMVs in our case) for 7-10 days, and lower seedling weight indicates that higher immune response is triggered (due to the trade-off between immunity and growth). Two E. coli strains were used, omp8 (Figure 2) and tolB (Figure 3), which can produce high and low immunogenic OMVs, respectively. For both strains, ClyA-flg22 and ClyA-elf18 OMVs seem to trigger stronger immune responses than OMVs containing only ClyA. However, the enhancement effect is more significant for tolB OMVs than omp8 OMVs. The reason might be that natural omp8 OMVs can already trigger strong immune responses, obscuring the additional immune responses triggered by flg22 or elf18.
Figure 2. Evaluation of engineered E. coli omp8 OMVs' immunogenicities by SGI assay.
Figure 3. Evaluation of engineered E. coli tolB OMVs' immunogenicities by SGI assay.
ROS (reactive oxygen species) burst assay was also used to test the immunogenicities of engineered OMVs (Figure 4), which shows how the leaf discs of A. thaliana Col-0 respond to OMV treatments within one to two hours. Both omp8 (Figure 4A, B) and tolB (Figure 4C, D) strains were used to produce OMVs, and both time-course ROS production curve (Figure 4A, C) and total ROS production (Figure 4B, D) are shown. Our results show that only ClyA-elf18 (Part:BBa_K3989011) OMVs, but not Cly-flg22 OMVs, can trigger significantly higher ROS production than ClyA-only OMVs, which is different from SGI assay where both constructs show enhancement effects.
Figure 4. Evaluation of engineered OMVs' immunogenicities by ROS burst assay.
Sequence and Features
- 10INCOMPATIBLE WITH RFC[10]Illegal PstI site found at 1105
- 12INCOMPATIBLE WITH RFC[12]Illegal PstI site found at 1105
- 21COMPATIBLE WITH RFC[21]
- 23INCOMPATIBLE WITH RFC[23]Illegal PstI site found at 1105
- 25INCOMPATIBLE WITH RFC[25]Illegal PstI site found at 1105
Illegal NgoMIV site found at 1099
Illegal AgeI site found at 1063 - 1000COMPATIBLE WITH RFC[1000]